Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Calendar quarter Q2 2026Earnings call Jul 30, 2026 · most recent call
BMY’s newest analyzed quarter is part of Tellvest Pro: its score, breakdown, narrative and analyst Q&A. Every prior quarter is free.
Sources. Scores: Bristol Myers Squibb’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: BMY daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
All prior quarters are free. How to browse earnings-call scores without Pro. How to read a company earnings-call score.
The breakdown for this quarter is part of Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $12.34B | +7.5% | $0.04 | -95.9% | 60.2% | 20.5% | 0.6% | $4.06B |
| FY2025 Q1 | $11.20B | -5.6% | $1.20 | +120.4% | 72.9% | 31.2% | 21.9% | $1.69B |
| FY2025 Q2 | $12.27B | +0.6% | $0.64 | -22.9% | 72.5% | 30.8% | 10.7% | $3.56B |
| FY2025 Q3 | $12.22B | +2.8% | $1.08 | +80.0% | 71.9% | 29.8% | 18.0% | $5.99B |
| FY2025 Q4 | $12.50B | +1.3% | $0.53 | +1401.4% | 67.2% | 22.5% | 8.7% | $1.60B |
| FY2026 Q1 | $11.49B | +2.6% | $1.31 | +9.2% | 70.2% | 29.3% | 23.3% | $757M |
| FY2026 Q2Selected | $12.97B | +5.7% | $1.62 | +153.1% | 71.3% | 31.5% | 25.6% | $3.95B |
Management-stated figures from BMY’s newest call are part of Tellvest Pro.
No 8-K events recorded since this call day.